{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:11:38Z","timestamp":1794863498289,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.curtheres.2023.100696","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T22:33:39Z","timestamp":1677105219000},"page":"100696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8160-7661","authenticated-orcid":false,"given":"William B.","family":"Ershler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"De Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Pakbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Moynahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Weycker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Delea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Agodoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2023.100696_bib0001","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"10091","key":"10.1016\/j.curtheres.2023.100696_bib0002","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.curtheres.2023.100696_bib0003","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J Clin Invest"},{"issue":"9442","key":"10.1016\/j.curtheres.2023.100696_bib0004","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(04)17192-4","article-title":"Sickle-cell disease","volume":"364","author":"Stuart","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.curtheres.2023.100696_bib0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/IJCTM.S96918","article-title":"Management of sickle cell disease: challenges and risks of transfusion","volume":"4","author":"Serjeant","year":"2016","journal-title":"Int J Clin Transfus Med"},{"issue":"20","key":"10.1016\/j.curtheres.2023.100696_bib0006","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1182\/blood.2021013873","article-title":"Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches","volume":"139","author":"Xu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.curtheres.2023.100696_bib0007","series-title":"Evidence-Based Management of Sickle Cell Disease","year":"2014"},{"issue":"9","key":"10.1016\/j.curtheres.2023.100696_bib0008","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00277-020-04057-8","article-title":"A study of the geographic distribution and associated risk factors of leg ulcers within an international cohort of sickle cell disease patients: the CASiRe group analysis","volume":"99","author":"Antwi-Boasiako","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.curtheres.2023.100696_bib0009","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/asheducation-2017.1.435","article-title":"Chronic organ failure in adult sickle cell disease","volume":"2017","author":"Vichinsky","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.curtheres.2023.100696_bib0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/03630269.2016.1224766","article-title":"Renal failure in sickle cell disease: prevalence, predictors of disease, mortality and effect on length of hospital stay","volume":"40","author":"Yeruva","year":"2016","journal-title":"Hemoglobin"},{"issue":"3","key":"10.1016\/j.curtheres.2023.100696_bib0011","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12024","article-title":"High one year mortality in adults with sickle cell disease and end-stage renal disease","volume":"159","author":"McClellan","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.curtheres.2023.100696_bib0012","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21550","article-title":"Definitions of the phenotypic manifestations of sickle cell disease","volume":"85","author":"Ballas","year":"2010","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.curtheres.2023.100696_bib0013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/bloodadvances.2021006281","article-title":"Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Advances"},{"issue":"9","key":"10.1016\/j.curtheres.2023.100696_bib0014","first-page":"1121","article-title":"The economic burden of end-organ damage among Medicaid Patients with sickle cell disease in the United States: a population-based longitudinal claims study","volume":"26","author":"Campbell","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"10.1016\/j.curtheres.2023.100696_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.curtheres.2023.100696_bib0016","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2019-127173","article-title":"Economic burden of end organ damage among patients with sickle cell disease in the US","volume":"134","author":"Song","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.curtheres.2023.100696_bib0017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ajh.21408","article-title":"The cost of health care for children and adults with sickle cell disease","volume":"84","author":"Kauf","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.curtheres.2023.100696_bib0018","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1182\/blood.V124.21.5971.5971","article-title":"Economic impact of sickle cell hospitalization","volume":"124","author":"Singh","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.curtheres.2023.100696_bib0019","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/pbc.22069","article-title":"Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States","volume":"53","author":"Mvundura","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.curtheres.2023.100696_bib0020","series-title":"Healthcare Cost and Utilization Project (HCUP) Statistical Briefs","article-title":"Sickle Cell Disease Patients in U.S. Hospitals","author":"Steiner","year":"2004"},{"issue":"1","key":"10.1016\/j.curtheres.2023.100696_bib0021","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12955-019-1225-7","article-title":"Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study","volume":"17","author":"Shah","year":"2019","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.curtheres.2023.100696_bib0022","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ajh.21883","article-title":"Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease","volume":"86","author":"Haywood","year":"2011","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.curtheres.2023.100696_bib0023","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/ehm.10.22","article-title":"Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities","volume":"3","author":"Brandow","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.curtheres.2023.100696_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229710","article-title":"Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease","volume":"15","author":"Saraf","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.curtheres.2023.100696_bib0025","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.curtheres.2023.100696_bib0026","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/asheducation-2016.1.625","article-title":"Sickle cell disease: when and how to transfuse","volume":"2016","author":"Howard","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"10.1016\/j.curtheres.2023.100696_bib0027","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3324\/haematol.2020.270546","article-title":"Red cell transfusion and alloimmunization in sickle cell disease","volume":"106","author":"Linder","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.curtheres.2023.100696_bib0028","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ajh.26063","article-title":"Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: results from the international Sickle Cell World Assessment Survey (SWAY)","volume":"96","author":"Osunkwo","year":"2021","journal-title":"Am J Hematol"},{"issue":"10037","key":"10.1016\/j.curtheres.2023.100696_bib0029","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/S0140-6736(16)00647-4","article-title":"Cardiovascular complications and risk of death in sickle-cell disease","volume":"387","author":"Gladwin","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.curtheres.2023.100696_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229959","article-title":"Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis","volume":"15","author":"Ataga","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.curtheres.2023.100696_bib0031","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/0033354919839072","article-title":"Improving an administrative case definition for longitudinal surveillance of sickle cell disease","volume":"134","author":"Snyder","year":"2019","journal-title":"Public Health Rep"},{"issue":"6","key":"10.1016\/j.curtheres.2023.100696_bib0032","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.curtheres.2023.100696_bib0033","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/01.HS9.0000848808.27158.0d","article-title":"P1488: association between hemoglobin levels and end-organ damage in sickle cell disease: a retrospective linked primary and secondary care database analysis in England","volume":"6","author":"Telfer","year":"2022","journal-title":"HemaSphere"},{"issue":"Suppl 2","key":"10.1016\/j.curtheres.2023.100696_bib0034","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1440-1797.2010.01314.x","article-title":"Proteinuria versus albuminuria in chronic kidney disease","volume":"15","author":"Guh","year":"2010","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"10.1016\/j.curtheres.2023.100696_bib0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/echo.12061","article-title":"The diagnostic accuracy of Doppler echocardiography in assessment of pulmonary artery systolic pressure: a meta-analysis","volume":"30","author":"Taleb","year":"2013","journal-title":"Echocardiography"},{"issue":"1","key":"10.1016\/j.curtheres.2023.100696_bib0036","first-page":"288","article-title":"Cerebrovascular accidents in sickle cell disease: rates and risk factors","volume":"91","author":"Ohene-Frempong","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.curtheres.2023.100696_bib0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0268-960X(93)90001-K","article-title":"Management of sickle cell disease; lessons from the Jamaican Cohort Study","volume":"7","author":"Serjeant","year":"1993","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.curtheres.2023.100696_bib0038","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-115-8-614","article-title":"Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality","volume":"115","author":"Powars","year":"1991","journal-title":"Ann Intern Med"},{"issue":"23","key":"10.1016\/j.curtheres.2023.100696_bib0039","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/bloodadvances.2019000916","article-title":"American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease","volume":"3","author":"Liem","year":"2019","journal-title":"Blood Adv"},{"issue":"3s","key":"10.1016\/j.curtheres.2023.100696_bib0040","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.annemergmed.2020.08.009","article-title":"Trends in sickle cell disease-related mortality in the United States, 1979 to 2017","volume":"76","author":"Payne","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"10","key":"10.1016\/j.curtheres.2023.100696_bib0041","doi-asserted-by":"crossref","first-page":"E345","DOI":"10.1002\/ajh.25233","article-title":"Opioid utilization patterns in United States individuals with sickle cell disease","volume":"93","author":"Ballas","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.curtheres.2023.100696_bib0042","unstructured":"Centers for Disease Control and Prevention. Data and statistics on sickle cell disease. Accessed January 25, 2023. https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html"},{"key":"10.1016\/j.curtheres.2023.100696_bib0043","unstructured":"Symphony Health. Fact Sheet. Key IDV\u00ae Statistics. Accessed January 25, 2023. https:\/\/s3.us-east-1.amazonaws.com\/prahs-symphony-health\/resources\/Symphony_IDV-Sheet_FINAL_JULY.pdf?mtime=20200702132440&focal=none"},{"issue":"18","key":"10.1016\/j.curtheres.2023.100696_bib0044","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X23000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X23000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:58:50Z","timestamp":1757897930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X23000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":44,"alternative-id":["S0011393X23000061"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2023.100696","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2023.100696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100696"}}